Brain and neurologic
This case study aims to describe the HTA processes and methods used in the adoption of an essential cancer drug such as trastuzumab in a selection of emerging countries in the use of HTA from the central, eastern and south eastern Europe (CESEE) and Latin America and the Caribbean (LAC) regions.
Dr Hafez Halawani talks to Oncology Central regarding the predictive and prognostic potential of tumor location in metastatic colorectal cancer – a debate that was perpetuated with the presentation of the Venook et al study at the 2016 ASCO meeting.
Explore the role of epigenetics in neuroendocrine prostate cancer in this peer-reviewed article from Epigenomics.
This review article from our partner journal Hepatic Oncology explores the immunology of hepatocellular carcinoma and details clinical trials investigating the efficacy of immune checkpoint blockade in the disease.
The authors review standard practices, current trends and controversies, and promising future therapies in muscle-invasive and metastatic bladder urothelial cancers.
Scientists have developed a urine test to predict the emergence of cervical cancer, for which preliminary studies confirm its accuracy and potential cost savings with regard to screening.
Head and neck
A calcium ion channel present in T cells has been identified by researchers as a potential target to reduce growth in head and neck cancer.
Researchers have demonstrated that acute myeloid leukemia patients who carry TP53 mutations respond better to a milder form of chemotherapy.
A pro-metastatic protein interaction has been identified in lung cancer and could present a potential future target.
This review article from Future Oncology explores the roles of miRNAs in pancreatic cancer development and the potential of miRNA-based therapeutics.
New investigation highlights preclinical efficacy of at combination of immune checkpoint inhibitors and therapies targeting myeloid-derived suppressor cells in advanced prostate cancer.
Randomized trials often require involvement of hundreds of patients to identify clinically meaningful differences – in terms or rare cancer, read as Ian Olver debates whether clinical trials should be approached differently in this opinion piece from Future Oncology.
This systematic review provides a comparative assessment of the efficacy and toxicity of combination or single-agent ipilimumab as immunotherapy of advanced melanoma.